References
- Gillmore JD, Lovat L, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid protein. Lancet 2001;358:24–9.
- Kuroda T, Tanabe N, Harada T, Murakami S, Hasegawa H, Sakatsume M, Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2006;25:498–505.
- Okuda Y, Takasugi K, Oyama T, Oyama H, Nanba S, Miyamoto T. Intractable diarrhea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis 1997;56:535–41.
- Nakamura T. Clinical strategies for amyloid A amyloidosis seco- ndary to rheumatoid arthritis. Mod Rheumatol 2008;18:109–18.
- Hazenberg BP, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Bailliere’s Clin Rheumatol 1994;8:661–90.
- Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation 2005;12:2047–60.
- Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaum F, Fautrel B, Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 2003;48:2019–24.
- Kuroda T, Wada Y, Kobayashi D, Murakami S, Sakai T, Hirose S, Effective anti-TNF-α therapy can induce rapid resolution and a sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 2009;36:2409–15.
- Chuang ES, Packer M, Hung-Lo K, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infli- ximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure. Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133–40.
- Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, Targeted anticytokine therapy in patients with chronic heart failure (RENEWAL). Circulation 2004; 109:1594–602.